Repligen jumps 4.6% as investors reprice 2026 growth and margins after guidance
Repligen shares rose 4.64% to $117.06 as investors continued to price in the company’s upbeat 2026 outlook after its Feb. 24, 2026 results and guidance update. The move also comes after fresh March conference messaging that reiterated faster growth in its Analytics franchise and margin expansion expectations for 2026.
1. What’s moving the stock
Repligen (NASDAQ: RGEN) traded higher Tuesday, up 4.64% to $117.06, as the market continued to reprice the company’s 2026 setup following its late-February earnings report and forward guidance. The company guided 2026 revenue of $810 million to $840 million, implying 9% to 13% organic growth (10% to 14% reported), alongside adjusted operating income of $122 million to $130 million, which points to year-over-year profit growth and operating margin expansion.
2. The fundamentals investors are leaning on
Management’s 2026 framework calls for Analytics growth above 20%, with other major franchises (including filtration and chromatography/proteins) targeted for low double-digit growth. Investors have also focused on the company’s messaging at March investor conferences, which emphasized execution priorities and reiterated the growth algorithm, helping keep attention on a recovery in bioprocessing demand and mix-driven improvement in profitability.
3. Recent corporate and Street backdrop
In early March, Repligen announced it would present at multiple investor conferences during the month, keeping the name in front of generalist and healthcare-focused funds. Separately, the company disclosed a board chair transition effective March 13, 2026, with the executive chair retiring and remaining an advisor through March 2027—an incremental governance update that removed a near-term overhang and kept focus on operating execution.